
Moderna Inc (NASDAQ:MRNA) submitted a request for FDA emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children six months to under six years of age.
The requests are based on a 25 μg two-dose primary series of mRNA-1273.

Moderna Inc (NASDAQ:MRNA) submitted a request for FDA emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children six months to under six years of age.
The requests are based on a 25 μg two-dose primary series of mRNA-1273.